Freeslate Chemical Development Summit Highlights Best Practices in High Throughput Research and Data Management

We’re pleased that the Chemical Development Summit supports open dialogue and the sharing of best practices around utilizing advanced automation and data management to dramatically enhance productivity.

Sunnyvale, CA (PRWEB) April 30, 2014

Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its Chemical Development Summit, held April 23 - 24, 2014 at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey. The meeting featured a tour of the BMS high throughput lab, customer case studies, and discussions of best practices in high throughput research and data management.

At this year’s Summit, chemical development professionals gathered to discuss the challenges and opportunities of high throughput chemistry research and to bring knowledge about best practices back to their organizations. The Summit consisted of formal case-study presentations by a diverse set of customers including Argonne National Lab, Bristol-Myers Squibb, Merck, and AstraZeneca, who highlighted their experience with Freeslate products to achieve dramatic innovation and rapid return on investment. Virscidian, a company focused on data processing for liquid chromatography (LC) and mass spectrometry (MS) data, offered a guest speaker which prompted a good dialogue around how to better aggregate reaction condition information with LC data. Hands-on training sessions were given by Freeslate staff who focused on accelerating productivity. A tour of the BMS facilities allowed attendees to see automation tools at work and discuss specific implementation with scientists and technicians. Networking between sessions and at evening events offered opportunities for one-on-one discussion and exchanging of new strategies and ideas.

“We recognize the unique challenges facing chemical development professionals today, who are under pressure to handle more projects with the same or less resources,” said John S. Senaldi, President and CEO of Freeslate. “We’re pleased that the Chemical Development Summit supports open dialogue and the sharing of best practices around utilizing advanced automation and data management to dramatically enhance productivity.”

Some of the key concepts that came out of the Summit included how to use automation to create kinetic Design of Experiment (DOE) studies and then manage the data to drive decision making. Other concepts included unique approaches to utilizing automation equipment to investigate new chemical research areas, building out tools that allow for searching across multiple data repositories, and finding better ways to link high throughput library designs with LC data.

Freeslate offers unique, high throughput systems for screening chemical reactions including automated powder dispensing systems, automated reaction screening systems, high throughput high pressure reactors, and a powerful data management suite for getting the most out of the data generated.

Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry. We start with a scientific understanding of our customer’s bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.